Skip to main content

Table 1 Clinico-pathological characteristics of the patients (n = 8703)

From: Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

Characteristics

Number of patients,

or median (range)

Percentage of the study population

Age, years

 median (range)

53.7 (21.8–90.9)

NA

Size of tumor

 T1

4042

46

 T2

3416

39

 T3–T4

1074

12

 missing data

171

2

Nodal status

 N0

4593

53

 N1

3052

35

 N2

575

7

 N3

219

3

 missing data

264

3

SBR grade

 I

689

8

 II

4034

46

 III

3730

43

 missing data

250

3

Inflammatory breast cancer

 yes

317

4

 no

8201

94

 missing data

185

2

Laterality

 right

4197

48

 left

4347

50

 bilateral

76

1

 missing data

83

1

Estrogen receptor status

 negative

2468

28

 positive

6191

71

 missing data

44

0.5

Progesterone receptor status

 negative

3717

43

 positive

4908

56

 missing data

78

1

HER2 status

 negative

5504

63

 positive

3199

37

Breast cancer subtypes

 triple-negative breast cancer

1115

13

 luminal breast cancer

4355

50

 HER2-positive breast cancer

3199

37

 missing data

34

0.4

Outcomes

 recurrences

1025

12

 deaths

423

5

- related to breast cancer

359

4

- unrelated to breast cancer

64

0.7

  1. SBR Scarff-Bloom-Richardson, HER2 human epidermal growth factor receptor 2, NA not applicable